DE69836582D1 - Kurze peptide die die aktivität serine/threonine kinasen modulieren - Google Patents

Kurze peptide die die aktivität serine/threonine kinasen modulieren

Info

Publication number
DE69836582D1
DE69836582D1 DE69836582T DE69836582T DE69836582D1 DE 69836582 D1 DE69836582 D1 DE 69836582D1 DE 69836582 T DE69836582 T DE 69836582T DE 69836582 T DE69836582 T DE 69836582T DE 69836582 D1 DE69836582 D1 DE 69836582D1
Authority
DE
Germany
Prior art keywords
modulate
threonine
kinasen
serine
short peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69836582T
Other languages
English (en)
Other versions
DE69836582T2 (de
Inventor
A Ben-Sasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Childrens Medical Center Corp
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem, Childrens Medical Center Corp filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of DE69836582D1 publication Critical patent/DE69836582D1/de
Application granted granted Critical
Publication of DE69836582T2 publication Critical patent/DE69836582T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
DE69836582T 1997-05-21 1998-05-20 Kurze peptide die die aktivität serine/threonine kinasen modulieren Expired - Lifetime DE69836582T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/861,338 US6174993B1 (en) 1997-05-21 1997-05-21 Short peptides which selectively modulate the activity of serine/threonine kinases
PCT/US1998/010319 WO1998053050A2 (en) 1997-05-21 1998-05-20 Short peptides which selectively modulate the activity of serine/threonine kinases
US861338 2001-05-18

Publications (2)

Publication Number Publication Date
DE69836582D1 true DE69836582D1 (de) 2007-01-18
DE69836582T2 DE69836582T2 (de) 2007-09-20

Family

ID=25335533

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836582T Expired - Lifetime DE69836582T2 (de) 1997-05-21 1998-05-20 Kurze peptide die die aktivität serine/threonine kinasen modulieren

Country Status (9)

Country Link
US (1) US6174993B1 (de)
EP (1) EP0983346B1 (de)
JP (1) JP2002500649A (de)
CN (1) CN1257538A (de)
AT (1) ATE347590T1 (de)
AU (1) AU734642B2 (de)
CA (1) CA2290721A1 (de)
DE (1) DE69836582T2 (de)
WO (1) WO1998053050A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285416B2 (en) 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US20020028772A1 (en) * 1997-05-21 2002-03-07 Children's Med. Corporation, Modulators of activity of G-protein-coupled receptor kinases
US7037891B2 (en) 1997-05-21 2006-05-02 Children's Medical Center Corporation Methods of modulating G-protein-coupled receptor kinase-associated signal transduction
CA2323574A1 (en) * 1998-03-26 1999-09-30 Gene Logic, Inc. Identification of a cdna associated with ischemia in human heart tissue
CA2343934A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
AU1942301A (en) * 1999-12-09 2001-06-18 Children's Medical Center Corporation Short peptides from the B4 and B5 regions of protein kinases which selectively modulate protein activity
CN1331319A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——sr蛋白特异性丝氨酸激酶212.98和编码这种多肽的多核苷酸
EP1385992A2 (de) * 2000-09-20 2004-02-04 Kinetek Pharmaceuticals, Inc. Mit krebs in zusammenhang stehende proteinkinasen und deren verwendungen
US20020115173A1 (en) * 2000-12-11 2002-08-22 Children's Medical Center Corporation Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity
CA2434831C (en) * 2001-01-17 2012-03-06 Robert H. Zimmer Polypeptide drug substances
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
JP2003230388A (ja) * 2001-12-05 2003-08-19 Sumitomo Pharmaceut Co Ltd 糖・脂質代謝異常疾患マーカーおよびその利用
FR2851460B1 (fr) * 2003-02-21 2007-05-11 Seppic Sa Utilisation de n-lauroyl aminoacides comme actif cosmetique et pharmaceutique amincissant
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
JP4819321B2 (ja) * 2003-12-15 2011-11-24 独立行政法人科学技術振興機構 Ａｋｔ活性特異的抑制ポリペプチド
SI1869020T1 (sl) 2005-03-29 2011-02-28 Icos Corp Derivati heteroaril uree, ki so uporabni za inhibicijo chk1
EP1877424A4 (de) * 2005-04-11 2010-09-29 Pharmagap Inc Inhibitoren von proteinkinasen und anwendungen davon
EP1878804A4 (de) * 2005-04-18 2009-09-23 Hubit Genomix Inc Gengrk5 in verbundung mit morbus perkinson und verwendung davon
JP5143729B2 (ja) * 2005-06-29 2013-02-13 ハダジット メディカル リサーチ サービシズ アンド ディベラップメント リミテッド インスリン抵抗性及び２型糖尿病の予防のためのプロテインキナーゼｃ阻害剤
JP5713614B2 (ja) * 2010-09-14 2015-05-07 スズキ株式会社 燃料電池システムおよび燃料電池車

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69323185T2 (de) 1992-02-24 1999-07-08 Smithkline Beecham Corp., Philadelphia, Pa. 19101 Proteinkinase c-inhibitor
US5935803A (en) 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta

Also Published As

Publication number Publication date
ATE347590T1 (de) 2006-12-15
JP2002500649A (ja) 2002-01-08
AU734642B2 (en) 2001-06-21
AU7583398A (en) 1998-12-11
EP0983346A2 (de) 2000-03-08
CA2290721A1 (en) 1998-11-26
US6174993B1 (en) 2001-01-16
DE69836582T2 (de) 2007-09-20
EP0983346B1 (de) 2006-12-06
WO1998053050A3 (en) 1999-02-25
WO1998053050A2 (en) 1998-11-26
CN1257538A (zh) 2000-06-21

Similar Documents

Publication Publication Date Title
DE69836582D1 (de) Kurze peptide die die aktivität serine/threonine kinasen modulieren
ATE399177T1 (de) Derivate therapeutischer peptide
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
BR9707819A (pt) Imunogenos peptidicos
CY1114164T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
LV11985A (lv) Noteiktu cistina atvasinajumu farmakologiska izmantosana
ES8604265A1 (es) Un metodo para preparar un peptido o una sal no toxica del mismo.
ATE419268T1 (de) Haemasterlin analoge
ES2190486T3 (es) 3-acetidinilalquilpiperidinas o -pirrolidinas como antagonistas de la taquicinina.
DK0852587T3 (da) Syntetiske peptider der inhiberer IL-6-aktivitet
NZ308516A (en) Transdermal therapeutic system (tts) for administering testosterone
DK0540574T3 (da) Antikoagulationspeptider
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
ID27162A (id) Peptida antigen tumor yang dibatasi hla-a2 yang berasal dari sart-1
DK0456792T3 (da) Forbedret transdermalt system til indgivelse af farmakologisk aktive forbindelser under pH-kontrollerede betingelser
ATE353958T1 (de) Modulatoren der aktivität von g-protein gekoppelten rezeptor kinasen
YU48719B (sh) Lizin so 6-hloro-5-fluoro-3-(2-tenoil)-2-oksindol-1-karboksamida
ATE222263T1 (de) Prostata-spezifische antigen inhibitore
ES2057624T3 (es) Sintesis de analogos de lr-rh con frecuencia minima temporal.
ATE404581T1 (de) Faserformgebende peptide, die mit selbstanordnenden peptiden interagieren
GR1001368B (el) Φαρμακευτικοί φορείς.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted